Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

T Cell Therapy's Most Valuable IP Placed On Open Market


News provided by

TCellTherapy.com

03 May, 2016, 19:07 GMT

Share this article

Share toX

Share this article

Share toX

PHOENIX and FRIBOURG, Switzerland, May 3, 2016 /PRNewswire/ -- In the midst of the most promising advance in the successful treatment, some even say, "cure," for cancer, perhaps the most elusive and frightening of all the world's widely-spread and often terminal diseases, $10's of billions are presently being invested by companies worldwide, in the development and forthcoming commercialization of a relatively new, yet recently proven, modality for successfully treating and frequently annihilating, various forms of cancer – T Cell Therapy AKA T Cell Immunotherapy, and its various sub-types, including Cellular Immunotherapy, Adoptive Immunotherapy, etc.

This image opens in the lightbox
T Cell Immunotherapy .COM Domain Names Now Offered For Sale at www.TCellTherapy.com

Photo - http://photos.prnewswire.com/prnh/20160503/363087

To assist the aforementioned corporate and biotechnology organizations in the forthcoming marketing, commercialization and sales of their various T Cell Therapy and T Cell Immunotherapy products to tackle cancer, 19-year veteran .COM Domain Name Broker, Neal Sutz, is today offering the world's most important, valuable and effective pieces of Internet Real Estate for this industry to the worldwide T Cell Therapy and T Cell Immunotherapy marketplace, via his project website – www.TCellTherapy.com.

Industry analysts and experts indicate in their analytics and subsequent industry growth and projected revenue reports that this "new, safer and more effective" treatment for various types of cancer is expected to attain a minimum of $30 Billion in annual revenues in the forthcoming five years, and then increasing at a rate of at least 100% for each subsequent year thereafter.  This growth is said to have been determined via intensive studies of the methodologies used in the creation of the reengineering the efficacy of T Cells to treat cancer in the most effective and apparently safest methods ever developed.  As the efficacy of T Cell Therapy becomes more accelerated and the efforts towards marketing and commercialization of the various T Cell Immunotherapy modalities (sub-types) become more aggressive and successful by those organizations wishing to achieve 1st place in the race to lead this burgeoning industry, the largest percentages of this projected industry market revenue is sure to be won by the companies most willing to invest in the appropriate and directly-targeted marketing methodologies and pieces of marketing-related Intellectual Property.

With major players such as Sean Parker, of Facebook and Napster fame, entering the T Cell Immunotherapy space, as well as every major and nearly every minor pharmaceutical, biotechnology, cancer research and treatment facility in the world diligently striving to be this infant industry's sales leader, it made unquestionably clear sense to Domain Broker, Neal Sutz, to acquire and centralize the largest collection ever assembled of T Cell Immunotherapy .COM domain names and offer them for sale in the open market via a worldwide PR campaign previously unmatched in the URL aftermarket sale space.

Sutz, via his project website at www.TCellTherapy.com, is presenting his URLS, without question the most important, valuable and pertinent .COM domain names ever offered to the open market, in an industry so groundbreaking so as to redefine the very way in which the world's most deadly disease, cancer, is approached with which to do battle. 

Sutz's industry-wide .COM domain name offering is based upon Big Pharma's 20-year pattern of spending millions of dollars of their annual marketing budgets on the acquisition and utilization of "generic" .COM domain names such as Depression.com, ProstateCancer.com, ADHD.com, CancerTreatment.com, etc. 

That fact, in addition to the $10's of millions that the aforementioned pharmaceutical and cancer treatment giants each spend annually to secure, strengthen and drive into the mind of the consumer the branded and trademarked names of their products, makes Sutz's T Cell Immunotherapy .COM domain names the most valuable and important marketing-related pieces of IP which any company, from Novartis to GSK to Celgene and the many other industry players, could possibly acquire and then utilize to dominate this new, highly-competitive marketplace.

Sutz is confident that the acquisition of any, if not all of his T Cell Therapy, et al. .COM domains, including but not limited to, TCellTherapy.com, TCellImmunotherapy.com, CellularImmunotherapy.com, ImmunotherapyVaccine.com, will be, by the right organization(s), the, "...most intelligent, powerful and effective IP acquisition that any of them could implement when determining their corporate strategies as to how best dominate the commercialization and profiting aspect of the world's most promising treatment avenue to tackle and lead the world's race to commercialize and profit from cancer therapy, unlike anything that the last 100 years have ever seen."

Sutz continued, "Based upon previous industry .COM domain name sales, in the mid-seven to low-eight figure range, such as Porn.com for $9.5M in an industry 2/3rds smaller than the projected T Cell Therapy industry revenue figures of at least $30 Billion in the first official year, I anticipate the sale of the URLS I have collected and am making available to companies which wish to have the most powerful tools to market their T Cell Therapy, et al. products, will join the ranks of the domain name resale industry's largest sales ever."

Sutz continued, "There is no other property currently on the open market that even compares to what I am offering.  After 19 years in this industry, having sold effective and valuable .COM domain names to over a dozen Big Pharma companies, and thousands of domain names to hundreds of other small, medium and large corporations in numerous other industries, I feel my skill set in the acquisition and offering of powerful, generic .COM domain names, especially a veritable monopoly as I have put together and am offering in this soon-to-be multi-billion dollar industry, has finally been put to the ultimate test in how to have acquired and how to properly promote the sale of, what are unquestionably the most valuable domain names currently on the market in the pharmaceutical and biotechnology industries."

Sutz's Immunotherapy Domain Name Auction can be reviewed and is being presented at the project URL, www.TCellTherapy.com.  All contact information with which to make an inquiry or bid can be found on the project's Home Page.

Related Links

http://www.TCellTherapy.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.